Early Immunotherapy May Spare Some Breast Cancer Patients Chemo

Triple-negative breast cancer represents a particularly aggressive subtype of the disease, characterized by the absence of hormone receptors and HER2 overexpression. This specific biological profile renders the tumour unresponsive to standard hormone therapies and HER2-targeted treatments, often resulting in a less favourable prognosis compared to other breast cancer subtypes. The condition is also more frequently diagnosed in younger women, adding a layer of complexity to its management. While significant progress has been made in treating advanced stages, the standard of care for patients with small, localised stage I tumours has traditionally relied on chemotherapy administered either before or after surgery, a regimen that carries substantial short- and long-term side effects.

Researchers at the Comprehensive Cancer Centre Gustave Roussy have presented preliminary findings from the POP-DURVA study, a prospective, multicentre, single-arm phase II trial designed to explore the potential of immunotherapy in this specific early-stage context. The study, presented at the European Society for Medical Oncology (ESMO) 2026 conference, investigated whether a very short course of immunotherapy could induce a sufficient antitumour response to potentially allow for treatment de-escalation in selected patients. Dr Joana Ribeiro, who led the oral presentation, emphasised the critical need to explore strategies that preserve treatment efficacy while reducing the burden of chemotherapy on patients who may not strictly require it.

The POP-DURVA trial enrolled 78 patients with stage I triple-negative breast cancer, specifically those with tumours measuring less than two centimetres and no clinically detectable lymph node involvement. A key eligibility criterion was the presence of at least 5% tumour-infiltrating lymphocytes (TILs), a marker indicating pre-existing immune activity within the tumour microenvironment. These patients received two injections of durvalumab, an anti-PD-L1 immune checkpoint inhibitor, administered fifteen days apart, prior to standard treatment which consisted of either surgery or preoperative chemotherapy. The primary objective was not to replace chemotherapy but to identify an early signal of activity and understand the biological mechanisms underlying sensitivity or resistance to immunotherapy.

The results, presented in October 2026, indicated that after only two injections of durvalumab and without concomitant chemotherapy, evidence of clinical activity was observed in a subset of patients. A major pathological response, defined as a substantial reduction in tumour burden, was achieved in approximately 11% of the cohort. Notably, the study reported the case of a 31-year-old patient in whom no residual tumour cells were found in the surgical specimen following only the two administrations of durvalumab. This observation suggests that a small number of patients display remarkable sensitivity to immunotherapy alone, a finding that Dr Ribeiro described as particularly encouraging given the brevity of the treatment course.

Beyond the immediate tumour shrinkage, one of the most significant findings from POP-DURVA concerns the profound changes observed within the tumour microenvironment. Analyses performed on paired pre- and post-treatment samples revealed that durvalumab induced increased mobilisation of immune cells within the tumours of several patients. Specifically, researchers observed an increase in tumour-infiltrating lymphocytes and a higher frequency of tertiary lymphoid structures (TLS). These TLS are organised aggregates of immune cells that play a crucial role in activating antitumour immune responses, suggesting that the treatment reshapes the immune landscape in a way that promotes a more robust defence against the cancer.

Molecular analyses further supported these microscopic observations. Among 62 patients with paired samples, RNA sequencing revealed increased expression of genes associated with immune activation and target-cell killing mechanisms. An exploratory analysis of 41 patients who proceeded directly to surgery after durvalumab treatment showed that greater increases in tumour-infiltrating lymphocytes were associated with lower proportions of residual viable tumour. These consistent changes at multiple levels, from cellular organisation to molecular signals, provide a deeper insight into how immunotherapy interacts with the tumour, although the long-term clinical significance of these biological remodelling effects remains to be established through further study.

The POP-DURVA study is part of UNLOCK, a flagship translational research programme of the PRISM Institute developed at Gustave Roussy. This initiative aims to better understand how innovative therapies, including immunotherapies, exert their effects by collecting tumour, blood, and stool samples at multiple time points throughout the patient journey. These samples are undergoing extensive analyses combining immunohistochemistry, RNA sequencing, and emerging single-cell biology approaches. Preliminary exploratory analyses at the individual-cell level have already provided insights into specific T-cell populations that may contribute to the immune signals observed, laying the groundwork for a more nuanced understanding of patient-specific responses.

The ultimate goal of the UNLOCK programme is to develop what Dr Ribeiro terms “true precision immunology.” By identifying the biological characteristics that distinguish patients who are particularly sensitive to immunotherapy from those who still require chemotherapy, researchers hope to better identify candidates for treatment de-escalation. This approach aims to limit patient exposure to more intensive therapies without compromising their chances of cure, thereby improving quality of life and reducing the risk of long-term side effects associated with chemotherapy. The findings from POP-DURVA suggest that while immunotherapy alone is not yet a standard replacement for chemotherapy in all early-stage triple-negative breast cancer patients, it holds significant promise for a tailored, less toxic treatment strategy for a specific subset of individuals.

Subject of Research: Exploring the potential of immunotherapy in early-stage triple-negative breast cancer

Article Title: Exploring the potential of immunotherapy in early-stage triple-negative breast cancer

Article References: Exploring the potential of immunotherapy in early-stage triple-negative breast cancer. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: Exploring, potential, immunotherapy, early-stage, triple-negative, breast, cancer, scientific research